Colon cancer patient tissues, but not normal colon mucosa cells, were sensitive to treatment with LXR agonists,9, 16 suggesting that LXRβ could be a promising target in cancer therapy. The gene discussed is NR1H2; the disease is malignant colon neoplasm.